市場調査レポート
商品コード
1123230
バイオマーカーの世界市場:2022-2028年Global Biomarker Market Research and Forecast 2022-2028 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
バイオマーカーの世界市場:2022-2028年 |
出版日: 2022年07月30日
発行: Orion Market Research
ページ情報: 英文 120 Pages
納期: 2~3営業日
|
世界のバイオマーカーの市場規模は予測期間中に14.6%のCAGRを示すと予測されています。
慢性疾患の高い有病率、診断用途でのバイオマーカー採用の増加、癌研究および臨床試験に対する政府の高い資金援助、創薬および開発への応用の増加などの要因が同市場の成長を推進しています。また、R&Dに対する政府のイニシアチブの増加、デジタルバイオマーカーなどの新技術、個別化医療における採用の増加も市場に有利な機会を生み出すと予想されています。
当レポートでは、世界のバイオマーカーの市場を調査し、市場概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。
Global Biomarker Market Size, Share & Trends Analysis Report by Type (Genomic Biomarker, and Protein Biomarker) By Application (Drug Discovery & Development, Diagnostic, Prognostic, Predictive, and Others ) By Disease (Cancer, Cardiac, Renal, Central Nervous System Disease, and Others) By End-User (Hospitals, Diagnostic Centre, and Research Institute) Forecast 2021-2027
The global market for a biomarker is projected to have a CAGR of 14.6% during the forecast period. A biomarker is an objective measure that captures what is happening in a cell or an organism at a given moment. Biomarkers can serve as early warning systems for health. Biomarkers can have molecular, histologic, radiographic, or physiological characteristics. The use of biomarkers in basic and clinical research as well as in clinical practice has become so commonplace that their presence as primary endpoints in clinical trials is now accepted almost without question. The key factors contributing to the growth of the global biomarker market include the high prevalence of chronic diseases, rising adoption of the biomarker for diagnostic applications, high government funding for cancer research and clinical trials, increasing application in drug discovery and development. According to the National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP) report, 6 in 10 adults in America live with at least one chronic disease, and 4 in 10 adults are with two or more. It is estimated that by 2060, the U.S. population aged 65 years and older will more than double, from 46 million today to 98 million. The high prevalence of chronic disease led to the demand for an effective biomarker which, in turn, further drive the market growth. The increase in the number of Contract Research Organizations (CROs) and the low cost of clinical trials in emerging economies are anticipated to further boost the growth of the market.
However, the high investments cost and low-cost benefit ratio and technical issues such as sample collection and storage are restraining the growth of the biomarker market. The increasing government initiatives for R&D, the introduction of new technologies such as digital biomarker and rising adoption in personalized medicine are expected to create lucrative opportunities for the market.
Segmental Outlook
The global biomarker market is segmented based on type, application, disease, and end-user. On the basis of type, the market is bifurcated into genomic and protein biomarker. The application segment is classified into drug discovery & development, diagnostic, prognostic, predictive and others (risk assessment). Among these, the biomarkers in drug discovery and development are anticipated to grow at significant CAGR during the forecast period. Biomarkers can predict the drug efficacy more quickly than conventional clinical endpoints, also they have the potential to accelerate product development in certain disease areas such as cancer, and cardiac disease. The disease segment is segregated into cancer, cardiac, renal, central nervous system disease and others (NASH). The end-user segment is categorized into hospitals, diagnostic center and research institute.
Global Biomarker Market Share by Disease, 2020 (%)
Global Biomarker Market Share by Disease
The Cancer disease segment holds the Major Market Share in the global Biomarker Market
Among disease, the biomarker in cancer dominated the market in 2020, and it is anticipated to maintain its dominance during the forecast period. Due to rise in prevalence of cancer cases across the globe, the demand for cancer biomarker has increased significantly in recent years, that has positively impacted the market growth. According to estimates from the International Agency for Research on Cancer (IARC), in 2018 there were 17.0 million new cancer cases and 9.5 million cancer deaths worldwide. By 2040, the global burden is expected to grow to 27.5 million new cancer cases and 16.3 million cancer deaths simply due to the growth and ageing of the population. According to the WHO data for cancer 2020, cancer is the main cause of death across the globe. There were 10 million deaths accounted for due to various types of cancer such as lung (1.80 million), colon and rectum (935 000), liver (8,30,000), stomach (769 000), and breast (685 000 deaths). In cancer research and drug discovery, biomarkers are used in three ways such as diagnostic (support to diagnose the condition in early-stage), prognostic (to forecast how aggressive a condition is), and predictive (to predict the response after treatment). The rising prevalence of cancer disease will increase the use of biomarkers in research-related activities which will further expected to drive the market growth.
Regional Outlook
Geographically, the global Biomarker market is classified into four major regions including North America (the US and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and Rest of the World (Latin America and the Middle East and Africa (MEA)). Among these, Asia-Pacific is the fastest-growing region during the forecast period. The factors contributing to the regional growth include the strong population base, high prevalence of chronic diseases such as cancer and CVDs in countries such as China, Japan, and India. Apart from this, improving biopharmaceutical research centers and rising clinical research in the region.
Global Biomarker Market Growth, by Region 2021-2027
Global Biomarker Market Growth, by Region
North America is projected to Dominate the Biomarker Market
Geographically, North America held the major market share in 2020, and it is anticipated to dominate the market during the forecast period. Major economies which contribute to the market are the US and Canada. Factors that are contributing significantly to the market growth include the presence of well-developed healthcare infrastructure, increasing healthcare R&D investments, high healthcare expenditure and others. The rising number of cancer patients is considered to be one of the major factors that are driving the growth of the market in the North American region. The healthcare expenditure rate of the US is more than that of Canada, as the US government invests more in R&D. Furthermore, socioeconomic factors such as health, income, population base creates more business opportunity in the US as compared to Canada.
Market Players Outlook
The key players in the biomarker market contributing significantly by providing different types of products and increasing their geographical presence across the globe. The key players of the market are Abbott Laboratories, Bio-Rad Laboratories Inc, Enzo Biochem Inc., EKF Diagnostics Holdings plc, PerkinElmer Inc, QIAGEN GmbH, Cisbio Bioassays, Johnson & Johnson Services, Inc., among others. To survive in the market, these market players adopt different marketing strategies such as mergers & acquisitions, R&D, product launches, and geographical expansions so on. For instance, in December 2020, Personalis, Inc. announced the launch of proprietary Neoantigen Presentation Score (NEOPS). It is a neoantigen-based composite biomarker for cancer immunotherapy response. NEOPS combines the tumor genomic and immune-related analytics of the Personalis, Next Platform in order to create a composite biomarker through which immunotherapy response can be predicted more effectively.
The Report Covers
Market value data analysis of 2020 and forecast to 2027.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global biomarker market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.